US Pharma MarketingLEO outlays $435m for rights to Tanabe’s rare disease drug for sun-induced pain
LEO outlays $435m for rights to Tanabe’s rare disease drug for sun-induced pain is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Tanabe’s dersimelagon is already under FDA review having achieved positive Phase III results earlier this year.
Source: Pharmaceutical Technology